News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2018

Liquid Biopsy Test for Liver Cancer Detection to obtain CE Mark

PDF -Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe -Prospective U.S. trial for FDA submission to be initiated in 2019 -Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), July 2, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) […]

Read more

Centers for Medicare & Medicaid Services publish preliminary rate for Epigenomics’ colorectal cancer screening test Epi proColon®

PDF Medicare Administrative Contractors determine rate of $192 per test Berlin (Germany) and Germantown, MD (U.S.A.), June 11, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the Centers for Medicare & Medicaid Services (CMS) published a preliminary rate of $192 per Epi proColon test. Epi proColon is the first and only FDA-approved […]

Read more

Centers for Medicare & Medicaid Services publish preliminary rate of $192 for Epigenomics’ colorectal cancer screening test Epi proColon®

PDF June 9, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced today that the Centers for Medicare & Medicaid Services (CMS) published a preliminary rate of $192 per Epi proColon test. Epi proColon is the first and only FDA-approved blood-based test for colorectal cancer screening. A press release with further details will be […]

Read more

Epigenomics AG: American Cancer Society published its updated colorectal cancer screening guidelines

PDF May 30, 2018 – Epigenomics AG announces that the Company’s blood-based colorectal cancer test Epi proColon® is not included in the updated colorectal cancer screening guidelines of the American Cancer Society published today. The Company will continue to pursue its goal to provide the significant unscreened patient population in the United States access to this […]

Read more

Epigenomics AG announces 2018 First Quarter Financial Results

PDF Berlin (Germany) and Germantown, MD (U.S.A.), May 9, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results for the first quarter 2018 ended March 31. Q1/2018 Financial results -Total revenue slightly increased to EUR 309 thousand (Q1 2017: EUR 281 thousand) due to higher product sales (+38%). […]

Read more

Epigenomics AG: Blood test shows promise in the detection of liver cancer

PDF -Results from two clinical studies demonstrate high sensitivity and specificity of mSEPT9 blood test -mSEPT9 test exhibited higher diagnostic accuracy than currently established diagnostic marker -Further independent, prospective clinical study with 440 patients initiated Berlin (Germany) and Germantown, MD (U.S.A.), April 19, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced promising results […]

Read more